Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 15OTHER 7UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Locally Advanced Malignant Neoplasm 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 5Capecitabine 5pyrotinib 4Epirubicin 4Docetaxel 4exemestane 3Vinorelbine 3Radiotherapy 3Radiation Dose Hypofractionation 3Fulvestrant 3Carboplatin 3apatinib 2Neoadjuvant Therapy 2Letrozole 2Etoposide 2Cyclophosphamide 2Albumin-Bound Paclitaxel 2toripalimab 1titanium silicide 1pirarubicin 1palbociclib 1nimotuzumab 1icaritin 1anlotinib 1Therapeutics 1Standard of Care 1Radiation 1Pemetrexed 1Nutrition Assessment 1Methods 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × Breast Neoplasms × Pemetrexed × Clear all
NCT02829008 2016-07-12

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

ChineseAMS

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡